RxDoctor Payments DataLook up a doctor →

David Navratil, MD

Clinical Cardiac Electrophysiology · Las Vegas, NVNPI 1043267024

Payments from drug & device makers

$29,373in general payments, 2019–2025

Across 505 payments — averaging $58.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$10K
  • Medtronic$4K
  • Atricure, Inc.$4K
  • Abbott$2K
  • Elutia, Inc.$2K
  • Novartis$833
  • plus $7K from 33 others

What the payments were for

  • Travel & lodging$7,98827%
  • Food & beverage$21,20372%
  • Education$1821%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,373 in reported general payments places this provider in the 60th percentile of 20 clinical cardiac electrophysiology providers in Nevada.

See all clinical cardiac electrophysiology providers in Nevada

Medicare billing

Part B allowed, 2024
$208,931
Medicare patients
479
Services billed
2,435

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban143$170,993
EntrestoSacubitril/Valsartan68$79,959
XareltoRivaroxaban50$58,673
MultaqDronedarone Hcl28$52,286
Propafenone Hcl ErPropafenone Hcl14$3,945
Flecainide Acetate71$2,723
Amiodarone Hcl109$2,478
Metoprolol Succinate176$2,366
Digoxin77$2,124
Verapamil ErVerapamil Hcl48$2,083
Nebivolol Hcl29$2,029
Dofetilide24$1,727
Verapamil SrVerapamil Hcl23$1,689
Propafenone Hcl30$1,524
Acebutolol Hcl27$1,469

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$50$170,993143 claims
NovartisEntresto$833$79,95968 claims
Johnson & JohnsonXarelto$790$58,67350 claims
Sanofi-aventis U.S. LLCMultaq$150$52,28628 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 20 clinical cardiac electrophysiology providers in Nevada.

Other clinical cardiac electrophysiology in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →